What changed: Prostate cancer
Every dated change on the records linked to Prostate cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
July 2026 · 1
June 2026 · 1
April 2026 · 1
March 2026 · 1
2026 · 3
- 2026ApprovalFlorastamin F-18Florastamin F-18 approved in South Korea
PET imaging of PSMA-positive lesions in men with prostate cancer whose existing imaging suggests recurrence or metastasis
- 2026ApprovalPiflufolastat F-18 / Pylarify TruVuPiflufolastat F-18 / Pylarify TruVu approved in US
Pylarify TruVu formulation
- 2026MilestonePSMAdditionPluvicto approved in metastatic hormone-sensitive disease (31 July); capivasertib + abiraterone approved for PTEN-deficient disease
A milestone in how this cancer is treated.
2025 · 5
- 2025ApprovalIlluccix (kit for Ga-68 gozetotide)Illuccix (kit for Ga-68 gozetotide) approved in US
Gozellix kit; selection of patients for PSMA-targeted radioligand therapy
- 2025Trial resultECLIPSEECLIPSE reported
rPFS significantly improved.
- 2025Trial resultPSMAdditionPSMAddition reported
rPFS HR 0.
- 2025MilestoneProstate cancerArteraAI Prostate: first predictive AI pathology test
A milestone in how this cancer is treated.
- 2025MilestonePSMAforePluvicto pre-chemotherapy (PSMAfore); ArteraAI Prostate FDA-authorised; PSMAddition positive; ECLIPSE positive; masofaniten discontinued
A milestone in how this cancer is treated.
2024 · 2
2023 · 5
- 2023ApprovalFlotufolastat F-18Flotufolastat F-18 approved in US
PSMA PET in prostate cancer
- 2023ApprovalPiflufolastat F-18 / Pylarify TruVuPiflufolastat F-18 / Pylarify TruVu approved in EU
EU brand Pylclari (Curium)
- 2023Trial resultEMBARKEMBARK reported
MFS HR 0.
- 2023Trial resultPSMAforePSMAfore reported
rPFS HR 0.
- 2023MilestoneEMBARKPARP + ARPI combinations approved (TALAPRO-2, PROpel, MAGNITUDE); EMBARK for biochemical recurrence
A milestone in how this cancer is treated.
2022 · 4
- 2022ApprovalLocametz (kit for Ga-68 gozetotide)Locametz (kit for Ga-68 gozetotide) approved in EU
PSMA PET in prostate cancer
- 2022ApprovalLocametz (kit for Ga-68 gozetotide)Locametz (kit for Ga-68 gozetotide) approved in US
PSMA PET in prostate cancer, including selection of patients for PSMA radioligand therapy
- 2022MilestoneLutetium-177 vipivotide tetraxetanPluvicto approved
A milestone in how this cancer is treated.
- 2022MilestoneLutetium-177 vipivotide tetraxetanPluvicto approved; ARASENS establishes triplet therapy
A milestone in how this cancer is treated.
May 2021 · 1
2021 · 7
- 2021ApprovalIlluccix (kit for Ga-68 gozetotide)Illuccix (kit for Ga-68 gozetotide) approved in Australia
PSMA PET imaging in prostate cancer
- 2021ApprovalIlluccix (kit for Ga-68 gozetotide)Illuccix (kit for Ga-68 gozetotide) approved in US
PSMA PET imaging in prostate cancer (initial staging with suspected metastasis; suspected recurrence)
- 2021ApprovalPiflufolastat F-18 / Pylarify TruVuPiflufolastat F-18 / Pylarify TruVu approved in US
PSMA PET imaging in prostate cancer
- 2021Trial resultPOP-RTPOP-RT reported
5-year biochemical failure-free survival 95% (whole pelvis) vs 81.
- 2021Trial resultTheraP (ANZUP 1603)TheraP (ANZUP 1603) reported
PSA50 66% vs 37%; OS HR 0.
- 2021Trial resultVISIONVISION reported
OS HR 0.
- 2021MilestoneVISIONVISION: 177Lu-PSMA-617 improves survival; TheraP beats cabazitaxel on response
A milestone in how this cancer is treated.
2020 · 4
- 2020ApprovalGallium-68 gozetotide (PSMA-11)Gallium-68 gozetotide (PSMA-11) approved in US
PSMA PET (UCLA/UCSF NDA); kits 2021-2022
- 2020Trial resultproPSMAproPSMA reported
Accuracy 92% vs 65%.
- 2020MilestonePSMA PETPSMA PET approved; olaparib in HRR-mutant mCRPC
A milestone in how this cancer is treated.
- 2020MilestoneGallium-68 gozetotide (PSMA-11)PSMA PET approved; PROfound approves olaparib for HRR-mutant mCRPC
A milestone in how this cancer is treated.
2018 · 2
2017 · 1
2016 · 3
- 2016ApprovalFluciclovine F-18Fluciclovine F-18 approved in US
PET imaging in men with suspected prostate cancer recurrence based on elevated PSA
- 2016Trial resultSTAMPEDESTAMPEDE reported
Abiraterone + ADT: OS HR 0.
- 2016MilestoneProstate cancerProtecT validates active surveillance
A milestone in how this cancer is treated.
2015 · 2
2013 · 3
2012 · 1
2011 · 3
- 2011ApprovalSodium fluoride F-18Sodium fluoride F-18 approved in US
Diagnostic PET imaging of bone to define areas of altered osteogenic activity (NDA 22-494, current labelling)
- 2011MilestoneProstate cancerAbiraterone approved
A milestone in how this cancer is treated.
- 2011MilestoneAbiraterone acetateAbiraterone approved; enzalutamide follows in 2012
Proof that castration-resistant disease is still AR-driven.
2004 · 1
1998 · 1
1997 · 1
1986 · 1
1972 · 2
- 1972ApprovalSodium fluoride F-18Sodium fluoride F-18 approved in US
Diagnostic PET imaging of bone to define areas of altered osteogenic activity (NDA 17-042)
- 1972ApprovalTechnetium Tc-99m medronate (MDP)Technetium Tc-99m medronate (MDP) approved in US
Bone imaging agent to delineate areas of altered osteogenesis